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NEW DEFINITION PROPOSED FOR
STEM CELL TRANSPLANTS
ASBMT and the American Society for
Hematology have jointly submitted rec-
ommendations for a re-definition of
stem cell transplantation in Medicare’s
manual for coverage determination.
The Centers for Medicare and Med-
icaid Services (CMS) invited recommen-
dations for new wording that would
recognize stem cell transplant and
high-dose chemotherapy as “both inte-
gral to the course of treatment and
covered as a single entity.”
Currently section 110.8.1 of the
National Coverage Determination
Manual states that stem cell transplan-
tation is a “process in which stem cells
are harvested from either a patient’s
or donor’s bone marrow or periph-
eral blood for intravenous infusion.
The transplant can be used to effect
hematopoietic reconstitution follow-
ing severely myelotoxic doses of che-
motherapy and/or radiotherapy used
to treat various malignancies. Alloge-
neic stem cell transplant may also be
used to restore function.”
Concerns have been raised about
misinterpretation of the definition in
light of current therapies. “High-dose
chemotherapy with autologous stem
cell transplant includes a number of
stages over a period of weeks,” CMS
said in an invitation for public com-
ment. “The first stage is called mobiliza-
tion, where the patient is given a
granulocyte colony-stimulating factor
(G-CSF) or a granulocyte-macrophage
colony-stimulating factor (GM-CSF) to
stimulate the release of the stem cells
from storage sites within the body.
Next, the stem cells are harvested via
leukapheresis or bone marrow biopsy.
The next stage is called conditioning,
where the patient is given a high dose
of a chemotherapy agent or radiother-
apy. In the final stage the harvested
stem cells are administered along with
supportive medical care.”
In a jointly prepared and submitted
statement, the presidents of ASBMT
and ASH, Drs. Nelson Chao and
James George, said that:
1. Consideration should be given to
separating allogeneic from autologous
stem cell transplant. Section 110.8.1
correctly states that “Autologous stem
cell transplants (AuSCT) must be used to
effect hematopoietic reconstitution fol-
lowing severely myelotoxic doses of
chemotherapy (HDCT) and/or radio-
therapy used to treat various malignan-
cies.” This can also be true for alloge-
neic transplant. More often, however,
allogeneic transplant is used to either
provide additional therapy to the un-
derlying malignancy via the effect of
the donor immune system or to correct
an underlying immune or inherited
problem via the normal function of the
donor hematopoietic stem cells. An-
other consideration in separating allo-
geneic from autologous stem cell trans-
plant is that the type, acuity and
duration of care differ significantly for
the two therapies.
2. The major components of hema-
topoietic stem cell transplant are donor
identification and evaluation, patient
evaluation, stem cell acquisition, deliv-
ery of the preparative regimen, stem
cell infusion, management until en-
graftment and post-transplant care.
3. It would be desirable to separate
hematopoietic stem cell acquisition
from the transplant itself. For autolo-
gous stem cell acquisition this should
encompass either bone marrow har-
vest or peripheral blood stem cell col-
lections. Chemotherapy is often deliv-
ered to the patient prior to autologous
peripheral blood stem cell harvest.
Since such chemotherapy is given with
the purpose of cytoreduction of the
malignancy as much as to enhance
mobilization of stem cells, it should be
excluded from stem cell acquisition. It
would be reasonable to include
growth factor administration such as
filgrastim as part of collection of either
allogeneic or autologous stem cell col-
lection. Allogeneic stem cell acquisition
should include bone marrow, periph-
eral blood stem cell and umbilical cord
blood as all are standard sources of
hematopoietic stem cells.
4. The start of the transplant
should be considered the first day of
delivery of the preparative regimen.
While the preparative regimen has
traditionally been performed as an
inpatient, it should be recognized
that the preparative regimen, the
transplant and much if not all of the
post-transplant care may be safely de-
livered as an outpatient in the appro-
priate setting.
5. We agree that the preparative
regimen and the stem cell transplant
are both integral to the therapy. The
intent of the preparative regimen
may vary by the type of transplant.
With autologous stem cell transplant,
severely myelotoxic doses of chemo-
therapy and radiotherapy will be
used. This may not be universally true
for allogeneic transplant as the intent
in some situations is to achieve en-
graftment to either allow an immuno-
logic effect of the donor graft against
malignancy or to correct an immune
or genetic deficiency.
6. The end of the transplant is more
difficult to define, but can generally be
considered engraftment. We suggest
that attainment of 500 neutrophils per
microliter of bloodmay be a reasonable
working definition. Recognition that
post-transplant care does not stop at
engraftment is important, and any-
thing post-engraftment should be con-
sidered post-transplant care.
7. Finally, we feel that the covered
indications for stem cell transplant are
overly restrictive and do not reflect stan-
dard of care. Additional indications for
allogeneic stem cell transplant should
include myelodysplastic syndrome,
non-Hodgkin’s lymphoma andmultiple
myeloma. Germ cell tumors should be
considered as an additional indication
for autologous transplant.
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